VSTM2A: A Potential Drug Target and Biomarker (G222008)

Target Name: VSTM2A

NCBI ID: G222008

VSTM2A

VSTM2A: A Potential Drug Target and Biomarker

Introduction

VSTM2A, also known as hypothetical protein MGC33530, is a protein that has been identified as a potential drug target and biomarker. It is a member of the voltage-dependent transmembrane protein (VSTM) family, which is known for its role in the regulation of ion channels and their function in various biological processes. The VSTM2A protein has been shown to play a crucial role in the regulation of neural excitability and has been linked to a number of neurological and psychiatric disorders.

Current Treatment Options

Current treatments for neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, and depression are limited in their effectiveness and often come with significant side effects. The search for new and more effective treatments has led to the development of drug targets, such as VSTM2A , which can be targeted with small molecules or antibodies to modulate its function and improve patient outcomes.

The Potential of VSTM2A as a Drug Target

The VSTM2A protein is a potential drug target due to its involvement in the regulation of neural excitability. It has been shown to play a role in the regulation of action potentials, which are the electrical signals that are generated by the entry of ions into the neural cell. The VSTM2A protein is also involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Targeting VSTM2A

VSTM2A is a protein that can be targeted with small molecules or antibodies. Small molecules can be used to modulate the activity of VSTM2A by binding to specific residues on the protein. Antibodies, on the other hand, can be used to target VSTM2A specifically and either block its function or enhance its activity.

One approach to targeting VSTM2A is to use small molecules that can modulate its activity in neural circuits. For example, a compound called P1-148 has been shown to inhibit the activity of VSTM2A and improve the sensitivity of neural cells to electrical stimulation.

Another approach to targeting VSTM2A is to use antibodies that can bind to specific residues on the protein. This approach is being developed by researchers at the University of California, San Diego, who have shown that antibodies against VSTM2A can improve the sensitivity of brain cells to electrical stimulation and protect against neurodegeneration.

Measuring the Effect of VSTM2A Intervention

To determine the effectiveness of VSTM2A intervention, researchers have used various techniques such as live cell imaging, patch-electrode recordings, and biochemical assays. These techniques allow researchers to monitor the activity of VSTM2A and measure the effects of its intervention on neural circuits.

For example, researchers at the University of California, San Diego, have used live cell imaging to monitor the activity of VSTM2A in neural circuits and have shown that the protein can modulate the activity of the electrical signals generated by the entry of ions.

Conclusion

VSTM2A is a protein that has been identified as a potential drug target and biomarker due to its involvement in the regulation of neural excitability. The search for new and more effective treatments for neurological and psychiatric disorders has led to the development of small molecules and antibodies that can target VSTM2A and modulate its function. Further research is needed to determine the effectiveness of VSTM2A intervention and to develop safe and effective treatments for a variety of neurological and psychiatric disorders.

Protein Name: V-set And Transmembrane Domain Containing 2A

Functions: Plays a role in the regulation of the early stage of white and brown preadipocyte cell differentiation. Promotes adipogenic commitment of preadipocytes by increasing gene expression of the transcription factor PPARG in a BMP4-dependent signaling pathway

The "VSTM2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSTM2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets